about
In silico pharmacophore model for tabun-inhibited acetylcholinesterase reactivators: a study of their stereoelectronic properties.Two-Step Mechanism of Cellular Uptake of Cationic Gold Nanoparticles Modified by (16-Mercaptohexadecyl)trimethylammonium Bromide.Structural requirements of acetylcholinesterase reactivators.The development of new oximes and the evaluation of their reactivating, therapeutic and neuroprotective efficacy against tabun.Design, evaluation and structure-activity relationship studies of the AChE reactivators against organophosphorus pesticides.Structure-activity relationship of quaternary acetylcholinesterase inhibitors - outlook for early myasthenia gravis treatment.Two possibilities how to increase the efficacy of antidotal treatment of nerve agent poisonings.The progress in the cholinesterase quantification methods.From pyridinium-based to centrally active acetylcholinesterase reactivators.Development and Structural Modifications of Cholinesterase Reactivators against Chemical Warfare Agents in Last Decade: A Review.Benzothiazoles - scaffold of interest for CNS targeted drugs.A Direct interaction between mitochondrial proteins and amyloid-β peptide and its significance for the progression and treatment of Alzheimer`s disease.Redox- and non-redox-metal-induced formation of free radicals and their role in human disease.Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment.Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs.SAR study to find optimal cholinesterase reactivator against organophosphorous nerve agents and pesticides.The interaction of quaternary reversible acetylcholinesterase inhibitors with the nicotinic receptor.Investigation of the reactivation kinetics of a large series of bispyridinium oximes with organophosphate-inhibited human acetylcholinesterase.Catalytic Soman Scavenging by the Y337A/F338A Acetylcholinesterase Mutant Assisted with Novel Site-Directed Aldoximes.Progress in acetylcholinesterase reactivators and in the treatment of organophosphorus intoxication: a patent review (2006-2016).Reactivation of VX-inhibited AChE by novel oximes having two oxygen atoms in the linker.(-)-CHANA, a fluorogenic probe for detecting amyloid binding alcohol dehydrogenase HSD10 activity in living cells.Quantification through TLC-Densitometric analysis, repellency and anticholinesterase activity of the homemade extract of Indian cloves.Eight new bispyridinium oximes in comparison with the conventional oximes pralidoxime and obidoxime: in vivo efficacy to protect from diisopropylfluorophosphate toxicity.Small Quaternary Inhibitors K298 and K524: Cholinesterases Inhibition, Absorption, Brain Distribution, and Toxicity.Design, Synthesis and in vitro Evaluation of Indolotacrine Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease.The present approaches to the development of prophylactic and therapeutic antidotes against nerve agents.Ligand-based 3D QSAR analysis of reactivation potency of mono- and bis-pyridinium aldoximes toward VX-inhibited rat acetylcholinesterase.A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats.In vitro ability of currently available oximes to reactivate organophosphate pesticide-inhibited human acetylcholinesterase and butyrylcholinesterase.Time-dependent changes of oxime K027 concentrations in different parts of rat central nervous system.Effect of seven newly synthesized and currently available oxime cholinesterase reactivators on cyclosarin-intoxicated rats.Reactivation kinetics of 31 structurally different bispyridinium oximes with organophosphate-inhibited human butyrylcholinesterase.Preparation of quinolinium salts differing in the length of the alkyl side chain.A comparison of neuroprotective efficacy of the oxime K203 and its fluorinated analogue (KR-22836) with obidoxime in Tabun-poisoned rats.Mono-oxime bisquaternary acetylcholinesterase reactivators with prop-1,3-diyl linkage-Preparation, in vitro screening and molecular docking.In vitro effects of acetylcholinesterase reactivators on monoamine oxidase activity.Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment.A comparison of the ability of newly-developed bispyridinium oxime K203 and currently available oximes (trimedoxime, obidoxime, HI-6) to counteract the acute neurotoxicity of soman in rats.A comparison of the potency of newly developed oximes (K347, K628) and currently available oximes (obidoxime, HI-6) to counteract acute neurotoxic effects of Tabun in rats.
P50
Q33520313-C72810F9-E0E5-45FF-AC00-D01E04773C33Q36125113-6BAA741C-A575-477D-9EEE-0394B884442FQ36412718-8B4E6FF1-9803-4900-9F2F-057AE2A0D0FDQ37294422-1A339007-2510-455D-A64D-99C4196F66AAQ37660998-5A97B115-FF53-4D28-B76E-42866EBADF67Q37719566-EE46D341-5AFA-4D24-9083-650C07C969B4Q37987609-339D1B61-5B3F-4C63-AC52-8BF77E2EE3D4Q38046649-5DB7DD9A-A364-412F-9CC6-6BF59036A342Q38189457-15663472-F49C-48DB-B09F-1AD9E57E4CDCQ38274155-6DA7B490-0444-4DEF-A9EF-1B1767285E62Q38290877-01E206CA-D33C-466A-A569-F2470A8943C7Q38331904-291097EF-A516-40E6-8E55-7B62615C02FCQ38581859-341DF2C0-E2D5-4444-8BEE-CBA096D589CDQ38771195-43DAA7CA-8EE2-4E4D-9DF3-FD22B51D20B1Q38875513-4F8F6481-5D73-4467-BDAA-749083CD53A0Q38942948-DBC578F3-C5C6-43E9-A6AC-436F6533FACCQ38962776-8AAA83F4-BC8E-4CE8-AF04-ED709C13BFF3Q38981213-41675C2A-58CD-4F39-BBB7-65DA68498CA6Q38989628-3067D032-FEC4-4EC0-B038-D183A618F530Q39343521-CDCE55E1-DD51-4866-9486-CC61B39F3228Q39725041-D7D26581-3DA2-4735-9757-9C49A4BC8624Q39838414-07DF9A6B-014A-4595-85D3-BAEFA5B79BECQ40037482-EB01F574-3EF5-4850-88F9-C0BBAFE3D962Q40082051-37B13358-97EF-481E-AC64-2B1412B51667Q40233361-9935FCC0-747C-4BE5-8E07-427EDB7C5282Q41276257-415CB1E9-C248-434F-BA70-2D914AC8BA5FQ41451713-0E75D8DA-16AD-4F35-A999-4657435551B7Q41583147-17F15FA8-2161-4F2F-BFFF-79F096C17A12Q41856128-5A491E22-1EDB-4ED2-A2DA-570C8DF275C4Q42102550-56935814-1674-4333-BEF4-05D8679249F2Q42506381-A23C402A-2200-42F4-8CFB-25E1F40C2E19Q42547753-638A97D3-16D2-4D22-92C6-F0DB0EB0B8A8Q42705289-F6B482D8-0378-4F8E-A8C9-08A9168932F6Q42717852-74A294E8-22CA-4FE0-AB15-41B808CAE9CCQ42718572-54C76E54-94E0-49F3-94D0-7B456AA75A2DQ42760217-F0849BE1-B351-4F00-81D2-FA55DF8FEF95Q42769225-2D15E56E-CC17-4F45-9055-78E664FF7A68Q42787028-25377689-F112-47DE-A74E-3FC5DE600ACCQ42926261-8C40EFBC-353E-4906-ABC0-7EB2BCD43BE3Q42951519-D5070A2E-BF44-4627-8781-23C4757A08EB
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Kamil Musílek
@ast
Kamil Musílek
@en
Kamil Musílek
@es
Kamil Musílek
@nl
Kamil Musílek
@sl
type
label
Kamil Musílek
@ast
Kamil Musílek
@en
Kamil Musílek
@es
Kamil Musílek
@nl
Kamil Musílek
@sl
prefLabel
Kamil Musílek
@ast
Kamil Musílek
@en
Kamil Musílek
@es
Kamil Musílek
@nl
Kamil Musílek
@sl
P214
P106
P1153
10540229700
P21
P214
P31
P496
0000-0002-7504-4062
P7859
viaf-305742016